TRI LOCUM PARTNERS LP
Q2 2024 Form 13-F
NEW YORK, NEW YORK
CIK 0001826434
· CRD 309678
· SEC-registered investment adviser
$395.5M Reported Value Total
TRI LOCUM PARTNERS LP reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $357,536,952, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $264.6M gross asset value
Hedge Fund: $264.6M
Source: Form ADV filed 2026-04-06
Reported value
$395.5M
Quarter over quarter
+0.3%
Holdings
25
Top-10 concentration
65.2%
Key People
Form ADV owners & control persons
Prashanth Nmn Jayaram
LIMITED PARTNER AND CHIEF INVESTMENT OFFICER
Jeffrey S Miller
CHIEF FINANCIAL OFFICER
Christabel Dee Syham
CHIEF BUSINESS OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $395.5M |
| Positions | 25 |
| Change in reported value | +37.2% |
| New positions | 10 |
| Exited positions | 12 |
| Position turnover | 59.5% |
| Top-10 concentration | 65.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
19 | $813.2M |
|
Q1 2026 13F
Filed May 18, 2026
|
17 | $712.5M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
15 | $770.1M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
18 | $435.1M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
23 | $329.5M |
|
Q1 2025 13F
Filed May 14, 2025
|
22 | $194.9M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
28 | $482.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
20 | $417.4M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
25 | $395.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
27 | $288.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
23 | $218.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
60 | $312.8M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
58 | $269.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
47 | $328.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
65 | $247.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
39 | $364.3M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
50 | $244.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
37 | $256.0M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
38 | $254.0M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
24 | $251.6M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | TEVA TEVA PHARMACEUTICAL INDS LTD | $41.4M | 10.48% |
| 2 | ARGX ARGENX SE | $32.1M | 8.11% |
| 3 | ASND ASCENDIS PHARMA A/S | $31.1M | 7.85% |
| 4 | AMGN AMGEN INC | $25.7M | 6.5% |
| 5 | NTRA NATERA INC | $25.0M | 6.31% |
| 6 | AXSM AXSOME THERAPEUTICS INC | $24.7M | 6.24% |
| 7 | INSM INSMED INC | $21.2M | 5.36% |
| 8 | MRUS MERUS N V | $19.9M | 5.02% |
| 9 | REGN REGENERON PHARMACEUTICALS | $18.4M | 4.65% |
| 10 | MDGL MADRIGAL PHARMACEUTICALS INC | $18.3M | 4.63% |
| 11 | INSP INSPIRE MED SYS INC | $17.8M | 4.51% |
| 12 | AVDL AVADEL PHARMACEUTICALS PLC | $16.7M | 4.23% |
| 13 | PFE PFIZER INC | $16.7M | 4.22% |
| 14 | UTHR UNITED THERAPEUTICS CORP DEL | $16.0M | 4.04% |
| 15 | LEGN LEGEND BIOTECH CORP | $15.8M | 3.99% |
| 16 | ALNY ALNYLAM PHARMACEUTICALS INC | $10.9M | 2.76% |
| 17 | STVN STEVANATO GROUP S P A | $10.4M | 2.62% |
| 18 | NVO NOVO-NORDISK A S | $9.1M | 2.3% |
| 19 | PCVX VAXCYTE INC | $8.6M | 2.16% |
| 20 | XENE XENON PHARMACEUTICALS INC | $4.0M | 1.01% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.